The chemotherapy of chagas' disease: an overview

Mini Rev Med Chem. 2005 May;5(5):499-519. doi: 10.2174/1389557053765565.

Abstract

The review presents: a) a brief description of the disease; b) a summary of the most important metabolic targets so far identified in Trypanosome cruzi (T. cruzi) along with corresponding inhibitor compounds; c) the current state of knowledge on the trypanothione reductase system of trypanosomatids with reference to oxidative stress defenses; d) detailed discussions on T. cruzi trypanothione reductase inhibitors such as nitrofuranes, naphthoquinones and phenothiazines. As yet, the chemotherapy of Chagas' disease remains an unsolved problem. Further search for new drugs must continue by means of nucleating existing chemotherapy efforts.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Chagas Disease / drug therapy*
  • Humans
  • NADH, NADPH Oxidoreductases / antagonists & inhibitors*
  • NADH, NADPH Oxidoreductases / metabolism
  • Trypanocidal Agents / chemistry
  • Trypanocidal Agents / pharmacology
  • Trypanocidal Agents / therapeutic use*
  • Trypanosoma cruzi / drug effects*
  • Trypanosoma cruzi / enzymology
  • Trypanosomatina / drug effects*
  • Trypanosomatina / enzymology

Substances

  • Trypanocidal Agents
  • NADH, NADPH Oxidoreductases
  • trypanothione reductase